In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 1, 1996, Pages 4-11

  Kim, Richard B ^a   Yamazaki, Hiroshi ^b   Chiba, Kan ^c   O'Shea, Diarmuid ^a   Mimura, Mayumi ^b   Guengerich, F Peter ^a   Ishizaki, Takashi ^c   Shimada, Tsutomu ^b   Wilkinson, Grant R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OSAKA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^c NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORZOXAZONE; CYTOCHROME P450 ISOENZYME;

ADULT; ARTICLE; ASIAN; CAUCASIAN; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG URINE LEVEL; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RACE DIFFERENCE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHLORZOXAZONE; CYTOCHROME P-450 CYP2E1; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; JAPAN; MALE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 0030436852     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. AHSAN, C. H., RENWICK, A. G., WALLER, D. G., CHALLENOR, V. F., GEORGE, C. F. AND AMANULLA, M.: The influence of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin. Pharmacol. Ther. 54: 329-338, 1993.
2. BERTILSSON, L., DAHL, M.-L., INGELMAN-SUNDBERG, M., JOHANSSON, I. AND SJÖQVIST, F.: Interindividual and interethnic differences in polymorphic drug oxidation. Implications for drug therapy with focus on psychoactive drugs. In Advances in Drug Metabolism in Man, ed. by G. M. Pacifici and G. N. Fracchia, European Commission, Brussels, pp. 85-136, 1995.
3. CARRIÈRE, V., BERTHOU, F., BAIRD, S., BELLOC, C., BEAUNE, P. AND DEWAZIERS, I.: Human cytochrome P4502E1 (CYP2E1): From genotype to phenotype. Pharmacogenetics 6: 203-211, 1996.
4. CASTAÑEDA-HERNÁNDEZ, G., HOYO-VADILLO, C., PALMA-AGUIRRE, J. A. AND FLORES-MURRIETA, F. J.: Pharmacokinetics of oral nifedipine in different populations. J. Clin. Pharmacol. 33: 140-145, 1993.
5. GIRRE, C., LUCAS, D., HISPARD, E., MENEZ, C., DALLY, S. AND MENEZ, J.-F.: Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem. Pharmacol. 47: 1503-1508, 1994.
6. GONZALEZ, F. J.: The molecular biology of the cytochrome P450s. Pharmacol. Rev. 40: 243-288, 1989.
7. GUENGERICH, F. P., WANG, P. AND DAVIDSON, N. K.: Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits and humans using immunochemical staining coupled with sodium dodecylsulfate-polyacrylamide gel electrophoresis. Biochemistry 21: 1698-1706, 1982.
8. GUENGERICH, F. P., KIM, D-H. AND IWASAKI, M.: Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem. Res. Toxicol 4: 168-179, 1991.
9. HAYASHI, S., WATANABE, J. AND KAWAJIRI, K.: Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P4502E1 gene. J. Biochem. 110: 559-565, 1991.
10. HECHT, S. S.: Metabolic activation and detoxification of tobacco-specific nitrosamines-A model for cancer prevention strategies. Drug Metab. Rev. 26: 373-390, 1994.
11. HIRVONEN, A., HUSGAFVEL-PURSIAINEN, K., ANTTILA, S., KARJALAINEN, A. AND VAINIO, H.: The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis 14: 85-88, 1993.
12. HUNT, C. M., STRATER, S. AND STAVE, E. M.: Effect of normal aging on the activity of human hepatic cytochrome P405IIE1. Biochem. Pharmacol. 40: 1666-1669, 1990.
13. IMAI, Y., ITO, A. AND SATO, R.: Evidence for biochemically different types of vesicles in the hepatic microsomal fraction. J. Biochem. 60: 417-428, 1966.
14. JAPANESE STATISTICS AND INFORMATION DEPARTMENT. VITAL STATISTICS, VOL. 1. JAPANESE MINISTRY OF HEALTH AND WELFARE, TOKYO, 1989.
15. KATO, S., SHIELDS, P. G., CAPORASO, N. E., HOOVER, R. N., TRUMP, B. F., SUGIMURA, H., WESTON, A. AND HARRIS, C. C.: Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res. 52: 6712-6715, 1992.
16. KATO, S., SHIELDS, P. G., CAPORASO, N. E., SUGIMURA, H., TRIVERS, G. E., TUCKER, M. A., TRUMP, B. F., WESTON, A. AND HARRIS, C. C.: Analysis of cytochrome P4502E1 genetic polymorphisms in relation to human lung cancer. Cancer Epidemiol. Biomarkers Prev. 3: 515-518, 1994.
17. KHARASCH, E. D. AND THUMMEL, K. E.: Identification of cytochrome P4502E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane and methoxyflurane. Anesthesiology 79: 795-807, 1993.
18. KHARASCH, E. D., THUMMEL, K. E., MHYRE, J. AND LILLIBRIDGE, J. H.: Single-dose disulfiram inhibition of chlorzoxazone metabolism: A clinical probe for P4502E1. Clin. Pharmacol. Ther. 53: 643-650, 1993.
19. KIM, R. B., O'SHEA, D. AND WILKINSON, G. R.: Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin. Pharmacol. Ther. 57: 645-655, 1995.
20. KOOP, D. R. AND TIERNEY, D. J.: Multiple mechanisms in the regulation of ethanol-inducible cytochrome P450IIE1. Bioessays 12: 429-435, 1990.
21. KOOP, D. R.: Oxidative and reductive metabolism by cytochrome P4502E1. FASEB J. 6: 724-730, 1992.
22. LIEBER, C. S.: Mechanisms of ethanol-drug nutrition interactions. Clin. Toxicol. 32: 631-681, 1994.
23. LOWRY, O. H., ROSEBOROUGH, N. J., FARR, A. L. AND RANDALL, R. L.: Protein measurements with the Folin phenol reagent. J. Biol. Chem. 193: 265-275, 1951.
24. LUCAS, D., MÉNEZ, C., GIRRE, C., BERTHOU, F., BODÉNEZ, P., JOANNET, I., HISPARD, E., BARDOU, L.-G. AND MÉNEZ, J.-F.: Cytochrome P4502E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics 5: 298-304, 1995.
25. MARCHAND, L. L., WILKENS, L. R. AND KOLONEL, L. N.: Ethnic differences in the lung cancer risk associated with smoking. Cancer Epidemiol. Biomarkers Prev. 1: 103-107, 1992.
26. MORIMOTO, M., HAGBJÖRK, A.-L., NANJI, A. A., INGELMAN-SUNDBERG, M., LINDROS, K. O., FU, P. C., ALBANO, E. AND FRENCH, S. W.: Role of cytochrome P4502E1 in alcoholic liver disease pathogenesis. Alcohol 10: 459-464, 1993.
27. NATIONAL INSTITUTES OF HEALTH, CANCER RATES AND RISKS. PUBLICATION NO. 85-691 UNITED STATES PUBLIC HEALTH SERVICE, BETHESDA, MD, 1985.
28. OMURA, T. AND SATO, R.: The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239: 2370-2378, 1964.
29. O'SHEA, D., DAVIS, S. N., KIM, R. B. AND WILKINSON, G. R.: Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: A putative probe of CYP2E1 activity. Clin. Pharmacol. Ther. 56: 359-367, 1994.
30. PERSSON, I., JOHANSSON, I., BERGLING, H., DAHL, M.-L., SEIDEDARD, J., RYLANDER, R., RANNUG, A., HÖGBERG, J. AND INGELMAN-SUNDBERG, M.: Genetic polymorphism of cytochrome P4502E1 in a Swedish population - relationship to incidence of lung cancer. FEBS Lett. 319: 207-211, 1993.
31. PETER, R., BÖCKER, R., BEAUNE, P. H., IWASAKI, M., GUENGERICH, F. P. AND YANG, C. S.: Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem. Res. Toxicol. 3: 566-573, 1990.
32. RAUCY, J. L., LASKER, J. M., LIEBER, C. S. AND BLACK, M.: Acetaminophen activation by human cytochromes P450IIE1 and P450IA2. Arch. Biochem. Biophys. 271: 270-283, 1989.
33. SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. AND GUENGERICH, F. P.: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270: 414-423, 1994.
34. TASSANEEYAKUL, W., VERONESE, M. E., BIRKETT, D. J., GONZALEZ, F. J. AND MINERS, J. O.: Validation of 4-nitrophenol as an in vitro substrate for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem. Pharmacol. 46: 1975-1981, 1993.
35. THUMMEL, K. E., KHARASCH, E. D., PODOLL, T. AND KUNZE, K.: Human liver microsomal enflurane defluorination catalyzed by cytochrome P-4502E1. Drug Metab. Dispos. 21: 350-357, 1993.
36. UEMATSU, F., KIKUCHI, H., MOTOMIYA, M., ABE, T., SAGAMI, I., OHMACHI, T., WAKUI, A., KANAMARU, R. AND WATANABE, M.: Association between restriction fragment length polymorphism of the human cytochrome P450IIE1 gene and susceptibility to lung cancer. Jpn. J. Cancer. Res. 82: 254-256, 1991.
37. UEMATSU, F., IKAWA, S., KIKUCHI, H., SAGAMI, I., KANAMARU, R., ABE, T., SATOH, K., MOTOMIYA, M. AND WATANABE, M.: Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancers: Possible relevance to low smoking exposure. Pharmacogenetics 4: 58-63, 1994.
38. WATANABE, J., HAYASHI, S.-I. AND KAWAJIRI, K.: Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5′-flanking region. J. Biochem. 116: 321-326, 1994.
39. WATANABE, J., YANG, J.-P., EGUCHI, H., HAYASHI, S.-I., IMAI, K., NAKACHI, K. AND KAWAJIRI, K.: An RsaI polymorphism in the CYP2E1 gene does not affect lung cancer risk in a Japanese population. Jpn. J. Cancer Res. 86: 245-248, 1995.
40. WILLIAMS, C. H. AND KAMIN, H.: Microsomal triphosphopyridine nucleotide-cytochrome c reductase of liver. J. Biol. Chem. 237: 587-595, 1962.
41. YAMAZAKI, H., INUI, Y., YUN, C. H., GUENGERICH, F. P. AND SHIMADA, T.: Cytochrome P4502E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13: 1789-1794, 1992.
42. 5 in the oxidation of 7-ethoxycoumarin, chlorzoxazone, aniline and N-nitrosodimethylamine by recombinant cytochrome P4502E1 and human liver microsomes. Biochem. Pharmacol. 52: 301-309, 1996.
43. YAMAZAKI, H., GUO, Z. AND GUENGERICH, F. P.: Selectivity of cytochrome P4502E1 in chlorzoxazone 6-hydroxylation. Drug Metab. Dispos. 23: 438-440, 1995.
44. YANG, C. S., YOO, J. S. H., ISHIZAKI, H. AND HONG, J.: Cytochrome P450IIE1: Roles in nitrosamine metabolism and mechanisms of regulation. Drug Metab. Rev. 22: 147-159, 1990.
45. YOO, J. S. H., GUENGERICH, F. P. AND YANG, C. S.: Metabolism of N-nitrosodialkylamines by human liver microsomes. Cancer Res. 48: 1499-1504, 1988.
46. ZAND, R., NELSON, S. D., SLATTERY, J. T., THUMMEL, K. E., KALHORN, T. F., ADAMS, S. P. AND WRIGHT, J. M.: Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin. Pharmacol. Ther. 64: 142-149, 1993.